行情

UTHR

UTHR

联合治疗
NASDAQ

实时行情|Nasdaq Last Sale

123.70
-2.00
-1.59%
交易中 09:37 06/04 EDT
开盘
124.43
昨收
125.70
最高
124.70
最低
123.25
成交量
2.08万
成交额
--
52周最高
125.94
52周最低
74.31
市值
54.44亿
市盈率(TTM)
10.31
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测UTHR价格均价为134.22,最高价位243.00,最低价为85.00。

EPS

UTHR 新闻

更多
The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week Highs June 3)
Benzinga · 1小时前
Zacks.com featured highlights include: SpartanNash Company, BG Foods, QIAGEN, Regeneron Pharmaceuticals and United Therapeutics
Zacks · 6天前
United Therapeutics Corporation to Present at the Jefferies Virtual Health Care Conference
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the Jefferies
PR Newswire · 05/26 10:00
Should You Own This Sleeper Biotech Stock?
MotleyFool.com · 05/22 15:58
Stocks That Hit 52-Week Highs On Tuesday
During Tuesday's morning trading, 59 companies set new 52-week highs.
Benzinga · 05/19 14:43
The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18)
Benzinga · 05/19 12:27
Stocks That Hit 52-Week Highs On Monday
During the morning session on Monday, 120 stocks hit new 52-week highs.
Benzinga · 05/18 14:44
Edited Transcript of UTHR earnings conference call or presentation 29-Apr-20 1:00pm GMT
Thomson Reuters StreetEvents · 05/17 17:19

所属板块

生物技术和医学研究
+0.02%
制药与医学研究
-0.21%

热门股票

代码
价格
涨跌幅

UTHR 简况

United Therapeutics Corporation是一家生物技术公司。该公司专注于开发及销售治疗慢性和危及生命状况的产品。该公司的治疗产品和候选产品包括前列环素类似物、5型磷酸二酯酶(PDE-5)抑制剂和单克隆抗体(MAb)。前列环素类似物主导产品为Remodulin(曲前列素)注射液。该公司的产品还包括Tyvaso(曲前列素)吸入溶液及Orenitram(曲前列素)延长释放片。其子公司正在开发另一种用于治疗肺动脉高压(PAH)的名为伊苏贝前列素的口服前列环素类似物。PDE-5抑制剂一种是治疗PAH的Adcirca(他达拉非)片剂。Unituxin(dinutuximab)注射剂与粒细胞-巨噬细胞集落刺激因子、白细胞介素-2和13-顺式维甲酸结合专注于治疗小儿神经母细胞瘤。
展开

微牛提供United Therapeutics Corporation(NASDAQ-UTHR)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的UTHR股票新闻,以帮助您做出投资决策。